poisar

Stocks · News reference

EU EMA Announces Sanofi Winthrop Industrie Withdrew Its Application For The Use Of Dupixent In The Treatment Of Adults With Moderate-To-Severe Bullous Pemphigoid On June 24

Benzinga Newsdesk

https://www.ema.europa.eu/en/medicines/human/variation/dupixent

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SNY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

    Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.

    MRNAGSKMRKSNY
  2. Na

    Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

    Eli Lilly announced a definitive agreement to acquire clinical-stage biotech Merida Biosciences for up to $2.875 billion in an all-cash transaction. The deal adds MER511 for Graves' disease and thyroid eye disease, along with preclinical candidates for allergy and kidney disease. This acquisition marks Lilly's 10th major deal in 2026 as the company diversifies its pipeline beyond cardiometabolic medicines, leveraging strong cash generation from its blockbuster GLP-1 drugs.

    LLYBMYCELGRSNY